- Integra Lifesciences Holdings Corp (NASDAQ: IART) reported Q4 adjusted EPS $0.84 better than the consensus estimate of $0.73 and revenues of $388.6 million in line with expectations.
- Revenues declined 1.6% Y/Y on a reported basis and a decrease of 1.5% on an organic basis, as the COVID-19 pandemic negatively impacted the surgical procedure volumes.
- The largest year-over-year revenue decline rates occurred in April, and surgical procedure volumes recovered over the balance of 2020. In Q4, surgical procedure volumes increased 5% sequentially.
- Adjusted net income of $71.3 million improved from $58.9 million in the prior-year quarter, primarily driven by the Company's actions to reduce operating expenses during the pandemic to mitigate the impact of lower sales.
- Adjusted EBITDA was $102.7 million, higher than $91.6 million a year ago. Cash flows from operations reached $80.3 million.
- The Company ended the quarter with $470.2 million in cash and cash equivalents, $1.2 billion in undrawn revolver capacity, and a consolidated total leverage ratio of 3.0x.
- For Q1 2021, the Company expects revenues from $345 million to $355 million, marginally lower than the consensus of $359.9 million. It sees adjusted EPS of $0.54 to $0.58 below the consensus estimate of $0.64.
- For 2021, Integra sees revenues in a range of $1.52 billion to $1.53 billion, short of $1.54 billion consensus and adjusted EPS of $2.86 to $2.93, compared to consensus of $2.92.
- The Company expects a reported revenue contribution from ACell in the range of $83 million to $88 million for 2021, with approximately $14 million to $15 million in Q1 of 2021. Integra completed the acquisition of ACell last month.
- Price Action: IART closed 2.4% higher at $71.15 on Wednesday.
IARTIntegra Lifesciences Holdings Corp
$16.720.12%
Edge Rankings
Momentum
20.84
Growth
36.58
Quality
-
Value
20.99
Price Trend
Short
Medium
Long
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Posted In:
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
